Table 2.
Comparison of patient characteristics between the clinical remission and non-clinical remission groups.
| Characteristics | Clinical Remission (n = 37) |
Non-Clinical Remission (n = 17) |
p-Value |
|---|---|---|---|
| Clinical characteristics | |||
| Age (years) | 64 (54–73) | 55 (47–73) | 0.333 |
| Duration of asthma (years) | 13 (4–28) | 27 (16–40) | 0.006 |
| Asthma onset ≥ 18 years, n (%) | 32 (86.5) | 10 (58.8) | 0.035 |
| Sex: male, n (%) | 17 (46.0) | 11 (64.7) | 0.249 |
| Body mass index (kg/m2) | 23.6 (20.5–26.1) | 25.0 (20.5–26.1) | 0.208 |
| Obesity | 11 (29.7) | 9 (52.9) | 0.134 |
| Former smoker, n (%) | 10 (27.0) | 12 (70.6) | 0.004 |
| Type 2 biomarker | |||
| Blood eosinophils (/μL) | 503 (372–909) | 478 (216–1153) | 0.635 |
| FeNO (ppb) | 67 (33–133) | 56 (42–101) | 0.802 |
| Atopy | 27 (73.0) | 10 (58.8) | 0.353 |
| Total serum IgE (IU/mL) | 347 (81–662) | 199 (70–675) | 0.635 |
| Comorbidity | |||
| Allergic rhinitis, n (%) | 24 (64.9) | 10 (58.8) | 0.765 |
| Chronic sinusitis, n (%) | 25 (67.6) | 12 (70.6) | 1.000 |
| Uncontrolled features | |||
| Exacerbation in the previous year, 0/1/≥2, n (%) | 17/8/12 (46.0/21.6/32.4) |
5/3/9 (29.4/17.7/52.9) |
0.140 |
| ACQ | 1.6 (1.0–2.2) | 2.4 (1.2–2.4) | 0.011 |
| FEV1 % predicted (%) | 91.5 (78.0–96.4) | 71.5 (49.4–84.2) | 0.0005 |
| Treatment | |||
| Use of ICS/LABA, n (%) | 17 (100.0) | 37 (100.0) | |
| Use of LAMA, n (%) | 21 (56.8) | 12 (70.6) | 0.383 |
| Use of maintenance OCS, n (%) | 10 (27.0) | 10 (58.8) | 0.035 |
| Maintenance OCS dose † (mg/day) | 8.0 (5.0–11.3) | 5.5 (5.0–10.0) | 0.501 |
| Type of biologics, Oma/Mep/Ben/Dup/Switch, n (%) | 4/1/14/11/7 (10.8/2.7/37.8/29.7/18.9) | 6/4/12/6/9 (16.2/10.8/32.4/16.2/24.3) | 0.131 |
Data are presented as the median (interquartile range) or n (%). † Maintenance OCS dose is provided as prednisone-equivalent for patients on chronic OCS therapy. LAMA, long-acting muscarinic antagonist; LTRA, leukotriene receptor antagonist; OCS, oral corticosteroid; Oma, omalizumab; Mep, mepolizumab; Ben, benralizumab; Dup, dupilumab; Switch, switched to biologic from other biologics; ACQ, asthma control questionnaire.